

Final-term Project
Xinyi Zhang (xiz4024)
28NOV2024

Introduction:

This final report is to report TFL (Table, Figure, Listing). All eligible patients had either Placebo or Drug B for their Treatment Group with all missing observations being removed. Only the first ten observations are listed. A Table-1 is presented, which is displaying the Age, BMI, Weight Status, and Average Cost summary statistics information for all eligible patients and separately for Placebo group and Drug B group. Figure 1 is presenting the histogram and Q-Q plot for distribution of age stratified by treatment group. Figure 2 is presenting the distribution of BMI stratified by sex and treatment group for adult patients older than 17 and younger than 70 years old.

Dataset:

xiz4024_forfinal.sas7bdat

Methods:

Unequal variance two-sample Student's t-test was used to test if there is any difference for the mean BMI score between Placebo and Drug B group. Chi-Square test was used to examine if there was any association between treatment group and different weight status. The Wilcoxon rank-sum test was applied to compare the distribution of average costs between the Placebo and Drug B groups. All analyses were performed in SAS9.4.

Results:

List of the first 10 patients

| Obs | Unique Subject ID | Treatment Group | AGE | SEX | BMI | Weight Status | Average Cost | Study end date |
|-----|-------------------|-----------------|-----|-----|------|---------------|--------------|----------------|
| 1 | 0000048 | Placebo | 34 | M | 17.2 | Underweight | | 01OCT2024 |
| 2 | 0000051 | Placebo | 25 | F | 9.6 | Underweight | \$100.95 | 01OCT2024 |
| 3 | 0000056 | Placebo | 74 | F | 21.0 | Normal Weight | \$23.58 | 01OCT2024 |
| 4 | 0000058 | Placebo | 22 | F | 23.2 | Normal Weight | \$33.28 | 01OCT2024 |
| 5 | 0000061 | Drug B | 50 | F | 25.2 | Overweight | \$54.68 | 01OCT2024 |
| 6 | 0000062 | Drug B | 51 | F | 30.3 | Obese | \$58.41 | 01OCT2024 |
| 7 | 0000064 | Placebo | 44 | M | 24.3 | Normal Weight | \$41.36 | 01OCT2024 |
| 8 | 0000065 | Drug B | 17 | M | 23.6 | Normal Weight | \$98.31 | 01OCT2024 |
| 9 | 0000067 | Drug B | 52 | M | 26.1 | Overweight | \$64.65 | 01OCT2024 |
| 10 | 0000068 | Placebo | 26 | M | 30.6 | Obese | \$65.57 | 01OCT2024 |

Table-1

| | Treatment Group | | | |
|-----------------------------|--------------------|---------------------|--------------------|---------------------|
| | Drug B (N=5884) | Placebo (N=5840) | Total (N=11724) | P-value |
| Age | | | | |
| N (Missing) | 5785 (99) | 5733 (107) | 11518 (206) | |
| Mean (SD) | 41.3 (23.70) | 41.3 (23.68) | 41.3 (23.69) | |
| Median (Range) | 41.0 (0.0, 84.0) | 41.0 (0.0, 83.0) | 41.0 (0.0, 84.0) | |
| BMI | | | | |
| | | | | 0.1089 ¹ |
| N (Missing) | 5683 (201) | 5635 (205) | 11318 (406) | |
| Mean (SD) | 21.5 (4.92) | 21.3 (4.92) | 21.4 (4.92) | |
| Median (Range) | 21.4 (3.4, 41.2) | 21.3 (3.2, 38.0) | 21.3 (3.2, 41.2) | |
| Weight Status, n (%) | | | | |
| | | | | 0.2511 ² |
| Morbidly Obese | 2 (0.0%) | 0 (0.0%) | 2 (0.0%) | |
| Normal Weight | 2851 (50.2%) | 2798 (49.7%) | 5649 (49.9%) | |
| Obese | 231 (4.1%) | 243 (4.3%) | 474 (4.2%) | |
| Overweight | 1091 (19.2%) | 1030 (18.3%) | 2121 (18.7%) | |
| Underweight | 1508 (26.5%) | 1564 (27.8%) | 3072 (27.1%) | |
| Missing | 201 | 205 | 406 | |
| Average Cost | | | | |
| | | | | 0.0330 ³ |
| N (Missing) | 5884 (0) | 5839 (1) | 11723 (1) | |
| Mean (SD) | 64.4 (24.70) | 63.3 (24.37) | 63.9 (24.54) | |
| Median (Range) | 63.6 (2.9, 194.5) | 62.8 (0.8, 199.0) | 63.2 (0.8, 199.0) | |

¹Unequal variance two sample t-test; ²Chi-Square p-value; ³Wilcoxon rank sum p-value;

Figure-1
Distribution of Age stratified by Treatment group
Variable:
AGE






Figure-2



Spearman Correlation Coefficient between BMI and Weight, Height, Age
Spearman Correlation Coefficient between BMI and WEIGHT HEIGHT AGE

| Variable | N | Mean | SD | Median | Min | Max | Spearman Coefficient (95% CI) | P-value ¹ |
|----------|-------|-------|-------|--------|------|--------|----------------------------------|----------------------|
| BMI | 11318 | 21.38 | 4.92 | 21.30 | 3.20 | 41.20 | | |
| WEIGHT | 11512 | 64.75 | 19.78 | 63.01 | 7.83 | 155.77 | 0.83 (0.83 - 0.84) | <.0001 |
| HEIGHT | 11530 | 1.73 | 0.14 | 1.73 | 1.23 | 2.18 | 0.18 (0.16 - 0.20) | <.0001 |
| AGE | 11518 | 41.33 | 23.69 | 41.00 | 0.00 | 84.00 | -0.01 (-0.03 - 0.01) | 0.4383 |

¹ P value of Spearman correlation coefficient, testing Ho: *Rho* = 0;

Note:

- 1. Only non-missing values are used within each pairs of variable for correlation;
- 2. P values and CIs are obtained with Fisher's Z-transformation with biasadj=no;
- 3. Correlation coefficient (*r*) is a measure of strength of correlation. As a rule-of-thumb, correlation strength can be categorized as:
 - 0.00 - 0.19: very weak;
 - 0.20 - 0.39: weak;
 - 0.40 - 0.59: moderate;
 - 0.60 - 0.79: strong;
 - 0.80 - 1.00: very strong;

Scatter plot with regression line and 95% confidence band

